Alternative Cancer Research Fund, Pheonix, AZ: ACRF is a non-profit international organization incorporated in the State of Arizona. ACRF's programs are dedicated to the collecting and distributing of information and educating the public about therapies, which have proven medicinal qualities, with emphasis placed on the treatment and prevention of cancer and other degenerative diseases.

British Columbia Cancer Agency, Vancouver, BC, Canada,   

Cancer Research Instutite, NY, USA. 

Fred Hutchinson Cancer Research Center, Seatle, WA, USA  

Georgia Cancer Coalition  

Markey Cancer Center, Lexington, KY:A comprehensive cancer center. Its mission is to eliminate the morbidity and mortality of cancer through a comprehensive program of research, education, clinical care and community outreach.

Memorial Sloan-Kettering Cancer Ctr., NY,NY: The OIA is responsible for protecting and licensing inventions developed by MSKC Center investigators, obtaining industrial funding for laboratories, and negotiating and reviewing private consulting agreements.

National Cancer Institute, Center for Cancer Research, USA  

National Cancer Institute. Division of Cancer  Biology

Nevada Cancer Institute, Las Vegas, NV:Mission is to reduce the burden of cancer by pursuing the development of a comprehensive cancer research institute, as defined by the National Cancer Institute, staffed by the finest scientists, clinicians, educators and caregivers.

UCSF Comprehensive Cancer Center, San Francisco, CA, USA.  

Biotech, Biopharmaceutical and Pharmaceutical Companies on Cancers and Treatments:

AmpliMed, Tucson, AZ: A clinical-stage pharmaceutical company discovers, develops and commercialises compounds for the treatment of cancer.

Biomarker Technologies, Inc., Pheonix, AZ: Provider of the BT Test, a blood test which uses a patented process to screen a blood sample for indications of breast cancer.

Dermagene Oy,  Tampere, Finland: NAV3 gene deletion test-kit for cancer diagnostics. NAV3 gene deletion assay (biomarker) services for pharmaceutical companies having investigational new drugs in Phage I/II clinical trials.

EMD Pharmaceuticals, Inc., Durham, NC. EMD Pharmaceuticals focuses on meeting patient and physician needs with pioneering pharmaceutical products and services with an initial emphasis on launching new products in oncology. 


Pacific Edge Biotechnology, Dunedin, New Zealand: PEBL is a technology leader in the application of novel molecular diagnostics for the development of new tools to enable the early detection and monitoring of cancer.

ProlX Pharmaceuticals, Tuscon, AZ:A biopharmaceutical company focused on the development of therapeutics for the treatment of cancer. ProlX is developing small-molecule drugs that inhibit redox and cell-survival signaling proteins.

Research VEGF: Genentech  

Zila Inc., Pheonix, AZ:An oncology diagnostic company initially focused on the prevention and detection of oral cancer. The company is dedicated to establishing its product as the new standard of care for the early detection of oral abnormalities that could lead to cancer. Zila Biotechnology is focused on achieving regulatory approval for the next generation oral cancer diagnostics as well as developing additional applications for its cancer detection technologies including products for the early detection of cervical and esophageal cancer.